Treatment Patterns in Essential Tremor: A Retrospective Analysis

Overview

Journal Tremor Other Hyperkinet Mov (N Y)

Publisher Ubiquity Press

Date 2022 Apr 13

PMID 35415009

Authors

Chintan Shah

George R Jackson

Aliya I Sarwar

Pitchaiah Mandava

Fariha Jamal

Affiliations

Soon will be listed here.

Abstract

Background: Although first line therapies for essential tremor have been identified from small clinical trials, responses are variable. We conducted a survey of tremor management in a large sample of ET cases.

Methods: The Movement Disorders Clinical Case Registry within a US Veterans Health Administration medical center was used to identify 1468 patients with ET.

Results: Of 1468 charts reviewed, 1074 (73.19%) met criteria for ET with characterization of temporal course and treatment; 291/1074 subjects (27.1%) did not receive any treatment. Almost half (500/1074; 46.6%) of the patients received monotherapy, 196/1074 (18.2%) two, 66/1074 (6.1%) three, and 21/1074 (2.0%) four or more medications. Of all prescriptions, primidone was the most used (546/1172; 46.6%), followed by propranolol (419; 35.8%), topiramate (122; 10.4%) and gabapentin (35; 3.0%). Medication response was available for a total of 1030 prescriptions, of which 138 (13.4%) were discontinued due to side effects; 180 (17.5%) prescriptions were ineffective. Furthermore, 52/1074 patients (4.8%) were treated with botulinum toxin injections and 41/1074 (3.8%) underwent deep brain stimulation surgery.

Discussion: Our data suggest that more widespread recognition of limitations underlying conventional approaches, as well as increased referrals for nonpharmacological therapies, may be necessary to achieve improved outcomes in ET populations.

Citing Articles

Tips and tricks in tremor treatment.

Hopfner F, Buhmann C, Classen J, Holtbernd F, Klebe S, Koschel J J Neural Transm (Vienna). 2024; 131(10):1229-1246.

PMID: 39043978 PMC: 11489236. DOI: 10.1007/s00702-024-02806-x.

Treatment patterns in essential tremor: Real-world evidence from a United Kingdom and France primary care database.

Antonazzo I, Rozza D, Conti S, Fornari C, Cortesi P, Eteve-Pitsaer C Eur J Neurol. 2023; 31(1):e16064.

PMID: 37738526 PMC: 11235796. DOI: 10.1111/ene.16064.

The Hidden Burden of Disease and Treatment Experiences of Patients with Essential Tremor: A Retrospective Claims Data Analysis.

Vetterick C, Lyons K, Matthews L, Pendal R, Ravina B Adv Ther. 2022; 39(12):5546-5567.

PMID: 36239902 PMC: 9618517. DOI: 10.1007/s12325-022-02318-8.

References

Louis E, Rios E, Henchcliffe C . How are we doing with the treatment of essential tremor (ET)?: Persistence of patients with ET on medication: data from 528 patients in three settings. Eur J Neurol. 2010; 17(6):882-4. PMC: 2889923. DOI: 10.1111/j.1468-1331.2009.02926.x. View

Diaz N, Louis E . Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. Parkinsonism Relat Disord. 2010; 16(9):604-7. PMC: 2963696. DOI: 10.1016/j.parkreldis.2010.07.011. View

Koller W, Biary N . Metoprolol compared with propranolol in the treatment of essential tremor. Arch Neurol. 1984; 41(2):171-2. DOI: 10.1001/archneur.1984.04050140069026. View

OSuilleabhain P, Dewey Jr R . Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord. 2002; 17(2):382-6. DOI: 10.1002/mds.10083. View

Serrano-Duenas M . Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord. 2003; 10(1):29-33. DOI: 10.1016/s1353-8020(03)00070-1. View

Louis E, Rohl B, Rice C . Defining the Treatment Gap: What Essential Tremor Patients Want That They Are Not Getting. Tremor Other Hyperkinet Mov (N Y). 2015; 5:331. PMC: 4548969. DOI: 10.7916/D87080M9. View

Ondo W, Hunter C, Vuong K, Schwartz K, Jankovic J . Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000; 15(4):678-82. DOI: 10.1002/1531-8257(200007)15:4<678::aid-mds1012>3.0.co;2-0. View

Zesiewicz T, Elble R, Louis E, Hauser R, Sullivan K, Dewey Jr R . Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005; 64(12):2008-20. DOI: 10.1212/01.WNL.0000163769.28552.CD. View

Bhatia K, Bain P, Bajaj N, Elble R, Hallett M, Louis E . Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2017; 33(1):75-87. PMC: 6530552. DOI: 10.1002/mds.27121. View

10.

Biary N, Koller W . Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology. 1987; 37(3):471-4. DOI: 10.1212/wnl.37.3.471. View

11.

Larsen T, Teravainen H, Calne D . Atenolol vs. propranolol in essential tremor. A controlled, quantitative study. Acta Neurol Scand. 1982; 66(5):547-54. DOI: 10.1111/j.1600-0404.1982.tb03141.x. View

12.

Louis E, McCreary M . How Common is Essential Tremor? Update on the Worldwide Prevalence of Essential Tremor. Tremor Other Hyperkinet Mov (N Y). 2021; 11:28. PMC: 8269764. DOI: 10.5334/tohm.632. View

13.

Brin M, Lyons K, Doucette J, Adler C, Caviness J, Comella C . A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001; 56(11):1523-8. DOI: 10.1212/wnl.56.11.1523. View

14.

Niemann N, Jankovic J . Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018; 10(7). PMC: 6070882. DOI: 10.3390/toxins10070299. View

15.

Calzetti S, Findley L, Gresty M, Perucca E, Richens A . Metoprolol and propranolol in essential tremor: a double-blind, controlled study. J Neurol Neurosurg Psychiatry. 1981; 44(9):814-9. PMC: 491142. DOI: 10.1136/jnnp.44.9.814. View

16.

Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J . A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996; 11(3):250-6. DOI: 10.1002/mds.870110306. View

17.

Hedera P, Cibulcik F, Davis T . Pharmacotherapy of essential tremor. J Cent Nerv Syst Dis. 2014; 5:43-55. PMC: 3873223. DOI: 10.4137/JCNSD.S6561. View

18.

Samotus O, Kumar N, Rizek P, Jog M . Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics. Can J Neurol Sci. 2017; 45(1):11-22. DOI: 10.1017/cjn.2017.260. View

19.

Louis E, Ferreira J . How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. 2010; 25(5):534-41. DOI: 10.1002/mds.22838. View

20.

Koller W, Busenbark K, Miner K . The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol. 1994; 35(6):717-23. DOI: 10.1002/ana.410350613. View